Nafenopin causes protein kinase C-mediated serine phosphorylation and loss of function of connexin 32 protein in rat hepatocytes without aberrant expression or localization.
The characteristics and mechanism of the inhibition of connexin-mediated gap junctional communication by the non-genotoxic rodent hepatocarcinogen, nafenopin, has been studied in rat hepatocytes. Nafenopin caused a time- and concentration-dependent inhibition of dye coupling in hepatocytes as assessed by transfer of microinjected lucifer yellow. A half-maximum inhibitory effect of nafenopin occurred at approximately 50 microM, which was not cytotoxic. The inhibitory effect was reversible since a significant recovery of communication was observed 3 h after removal of the chemical. The protein kinase inhibitor Gö6976 prevented the inhibition of dye coupling, but a tyrosine kinase inhibitor (genistein) did not. Connexin 32 and 26 protein expression, as assessed by immunoblotting, was similar in nafenopin-treated hepatocytes compared to controls, with the exception that in a 10-h culture with nafenopin, the level of connexin 26 was elevated compared to controls. Immunohistochemistry indicated that the localization of plaques containing connexin 32 was not affected in hepatocytes by nafenopin. Immunoprecipitated connexin 32 was, however, detected by an anti-phosphoserine antibody following nafenopin treatment, but not in controls. This serine phosphorylation was prevented in the presence of Gö6976. The results give further support for a role of protein kinase C in the post-translational inactivation of connexin 32 function in rat hepatocytes by nafenopin.
Elcock
F J
FJ
School of Biosciences, The University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom.
Deag
E
E
Roberts
R A
RA
Chipman
J K
JK
D000818:Animals; D002478:Cells, Cultured; D017630:Connexins / Q000235:genetics / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D017629:Gap Junctions / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D019833:Genistein / Q000494:pharmacology; D015151:Immunoblotting; D008099:Liver / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D018613:Microscopy, Confocal; D009255:Nafenopin / Q000494:pharmacology*; D020025:Peroxisome Proliferators / Q000494:pharmacology*; D010766:Phosphorylation; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012694:Serine / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D000097002:Gap Junction beta-1 Protein
D017630:Connexins; D004791:Enzyme Inhibitors; D019833:Genistein; D009255:Nafenopin; D020025:Peroxisome Proliferators; D011493:Protein Kinase C; D012333:RNA, Messenger; D012694:Serine; D000097002:Gap Junction beta-1 Protein